OmniAb Inc. (OABI) - Total Liabilities
Based on the latest financial reports, OmniAb Inc. (OABI) has total liabilities worth $31.00 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore OABI year-over-year net asset growth to track the company's year-over-year net asset growth rate.
OmniAb Inc. - Total Liabilities Trend (2019–2025)
This chart illustrates how OmniAb Inc.'s total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of OmniAb Inc. to measure how efficiently the company converts operating cash flow to free cash.
OmniAb Inc. Competitors by Total Liabilities
The table below lists competitors of OmniAb Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Richtech Robotics Inc. Class B Common Stock
NASDAQ:RR
|
USA | $9.74 Million |
|
Energy Services Of America Corp
NASDAQ:ESOA
|
USA | $116.43 Million |
|
Sungwoo Hitech Co. Ltd
KQ:015750
|
Korea | ₩3.01 Trillion |
|
Schweizerische Nationalbank
SW:SNBN
|
Switzerland | CHF724.25 Billion |
|
Funko Inc
NASDAQ:FNKO
|
USA | $456.73 Million |
|
Vinacafe Bien Hoa JSC
VN:VCF
|
Vietnam | ₫588.19 Billion |
|
FM Mattsson Mora Group AB (publ)
ST:FMM-B
|
Sweden | Skr804.50 Million |
|
Pss Co Ltd
TW:6914
|
Taiwan | NT$6.63 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down OmniAb Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of OmniAb Inc..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OmniAb Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OmniAb Inc. (2019–2025)
The table below shows the annual total liabilities of OmniAb Inc. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $33.89 Million | -10.68% |
| 2024-12-31 | $37.94 Million | -37.43% |
| 2023-12-31 | $60.64 Million | -24.05% |
| 2022-12-31 | $79.84 Million | +13.80% |
| 2021-12-31 | $70.16 Million | +17.24% |
| 2020-12-31 | $59.84 Million | +35.59% |
| 2019-12-31 | $44.13 Million | -- |
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more